Skip to main content
Guangzhou Innogen Pharmaceutical Group Co., Ltd. logo

Guangzhou Innogen Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 2591 HKEX Manufacturing
Open in API
Filings indexed 45 across all filing types
Latest filing 2025-12-07 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2591

About Guangzhou Innogen Pharmaceutical Group Co., Ltd.

https://www.innogenpharm.com

Guangzhou Innogen Pharmaceutical Group Co., Ltd. is a science-driven company focused on the discovery, development, and commercialization of innovative therapies for metabolic diseases. The company targets high-prevalence conditions including diabetes, obesity, and metabolic dysfunction-associated steatohepatitis (MASH), alongside central nervous system disorders. Its primary product, Supaglutide alpha, is a humanized long-acting GLP-1 receptor agonist developed to provide effective treatment for diabetes. Innogen utilizes a proprietary recombinant protein biological drug technology platform to maintain a self-developed pipeline with global intellectual property rights. The organization is led by a team of specialists with extensive experience in metabolic research, aiming to deliver accessible and high-quality therapeutic solutions to global markets.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE COMPANY'S CORE PRODUCT IN THE NATIONAL REIMBURSEMENT DRUG LIST
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement issued by Guangzhou Innogen Pharmaceutical Group Co., Ltd. regarding the inclusion of its core product, Efsubaglutide Alfa, in the National Reimbursement Drug List (NRDL). It does not constitute a financial report, a proxy statement, or a regulatory filing of a specific form type (like 10-K or IR). As it is a general corporate announcement regarding business development that does not fit into the specific categories of M&A, dividends, or director dealings, it is classified as a general regulatory announcement.
2025-12-07 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in their securities, share capital, and treasury shares. Since it does not fit into specific categories like 'Share Issue' (which usually refers to a specific event announcement) or 'Transaction in Own Shares' (which is for specific buybacks), and it is a recurring regulatory filing mandated by the Exchange Listing Rules, it is best classified as a Regulatory Filing (RNS).
2025-12-03 English
DISCLOSEABLE TRANSACTION IN RELATION TO SUBSCRIPTION OF STRUCTURED DEPOSIT PRODUCTS
Regulatory Filings Classification · 1% confidence The document is an official announcement regarding a 'Disclosable Transaction' involving the subscription of structured deposit products by the company and its subsidiary. It explicitly references the Listing Rules of the Stock Exchange of Hong Kong, specifically Chapter 14 regarding reporting and announcement requirements for transactions. While it involves financial products, it is not a periodic financial report, nor is it an M&A activity (TAR) or a capital raise (CAP). It is a regulatory disclosure of a corporate transaction, which falls under the 'Regulatory Filings' (RNS) category as the most appropriate fallback for miscellaneous regulatory announcements that do not fit into more specific categories like M&A or Share Issues.
2025-12-01 English
ANNOUNCEMENT REGARDING THE POSTPONEMENT OF THE RE-ELECTION OF THE BOARD AND THE SUPERVISORY COMMITTEE
Regulatory Filings Classification · 1% confidence The document is an official announcement from Guangzhou Innogen Pharmaceutical Group Co., Ltd. regarding the postponement of the re-election of its Board of Directors and Supervisory Committee. It does not announce a change in personnel (which would be MANG) but rather a procedural delay in the election process. As it is a regulatory announcement regarding corporate governance and board structure that does not fit into specific categories like MANG or CGR, it is best classified as a general regulatory filing.
2025-11-21 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025
Regulatory Filings Classification · 1% confidence The document is a statutory monthly return filed under HKEX Listing Rules Chapter 19B, detailing movements in authorised, issued, and treasury share capital for October 2025. It is not a financial performance report (10-K/IR/ER), not a management or investor presentation, and not announcing a report publication. It instead constitutes a routine regulatory filing for share capital movements under exchange rules, fitting the fallback “Regulatory Filings” category (RNS).
2025-11-05 English
DISCLOSEABLE TRANSACTION IN RELATION TO SUBSCRIPTION OF STRUCTURED DEPOSIT PRODUCTS
Regulatory Filings Classification · 1% confidence The document is a Hong Kong Stock Exchange announcement of a ‘‘disclosable transaction’’ under Chapter 14 of the Listing Rules, describing the company’s subscription of RMB105 million of structured deposit products with a bank for treasury management purposes. It is not an earnings release or full report, nor a share issue or M&A, but a regulatory‐mandated announcement of a financial transaction that does not fit a more specific category. Therefore it falls into the fallback ‘‘Regulatory Filings’’ category (Code: RNS).
2025-11-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.